Citadel Advisors
BNTX icon

Citadel Advisors’s BioNTech BNTX Stock Holding History

Citadel Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.9M Sell
364,585
-586,787
-62% -$55.2M ﹤0.01% 1965
2026
Q1 		$84.6M Buy
951,372
+273,197
+40% +$28.1M 0.01% 932
2025
Q4 		$64.6M Buy
678,175
+288,680
+74% +$29.1M 0.01% 1197
2025
Q3 		$38.4M Buy
389,495
+386,783
+14,262% +$41.4M 0.01% 1638
2025
Q2 		$289K Sell
2,712
-218,478
-99% -$22.1M ﹤0.01% 9897
2025
Q1 		$20.1M Buy
221,190
+93,759
+74% +$10.5M ﹤0.01% 2028
2024
Q4 		$14.5M Buy
127,431
+88,527
+228% +$10.1M ﹤0.01% 2531
2024
Q3 		$4.62M Sell
38,904
-27,308
-41% -$2.51M ﹤0.01% 4053
2024
Q2 		$5.32M Sell
66,212
-412,668
-86% -$37.7M ﹤0.01% 3645
2024
Q1 		$44.2M Buy
478,880
+448,933
+1,499% +$43M 0.01% 1316
2023
Q4 		$3.16M Sell
29,947
-28,199
-48% -$2.84M ﹤0.01% 4546
2023
Q3 		$6.32M Sell
58,146
-136,062
-70% -$15M ﹤0.01% 3303
2023
Q2 		$21M Buy
194,208
+187,519
+2,803% +$21.1M ﹤0.01% 1835
2023
Q1 		$833K Sell
6,689
-125,602
-95% -$17.2M ﹤0.01% 7196
2022
Q4 		$19.9M Buy
132,291
+108,750
+462% +$16.7M ﹤0.01% 1973
2022
Q3 		$3.17M Sell
23,541
-264,344
-92% -$40.4M ﹤0.01% 4699
2022
Q2 		$42.9M Buy
287,885
+116,888
+68% +$17.9M 0.01% 1146
2022
Q1 		$29.2M Sell
170,997
-70,295
-29% -$11.8M 0.01% 1581
2021
Q4 		$62.2M Sell
241,292
-35,808
-13% -$9.81M 0.01% 1001
2021
Q3 		$75.6M Buy
277,100
+64,532
+30% +$20.5M 0.02% 830
2021
Q2 		$47.6M Buy
212,568
+14,535
+7% +$2.74M 0.01% 1169
2021
Q1 		$21.6M Sell
198,033
-68,705
-26% -$7.3M 0.01% 1863
2020
Q4 		$21.7M Buy
266,738
+124,192
+87% +$12.2M 0.01% 1713
2020
Q3 		$9.87M Sell
142,546
-212,615
-60% -$15.3M ﹤0.01% 2312
2020
Q2 		$23.7M Buy
+355,161
New +$17.7M 0.01% 1363

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Citadel Advisors's BNTX Position: Q2 2026 in Review

Citadel Advisors reduced its BioNTech (BNTX) stake by 62% in Q2 2026, selling an estimated $55.2M and leaving 364,585 shares worth $33.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Citadel Advisors first reported a position in BNTX in Q2 2020 and has held it in 25 quarters since. The position peaked at $84.6M in Q1 2026. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Citadel Advisors held 364,585 shares of BioNTech worth $33.9M as of Q2 2026.
  • Citadel Advisors sold 586,787 BioNTech shares in Q2 2026, an estimated $55.2M.
  • BioNTech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1965 holding.
  • Citadel Advisors first reported a position in BioNTech in Q2 2020 and has held it in 25 quarters since.
  • Citadel Advisors's BioNTech position peaked at $84.6M in Q1 2026.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.